1312692-16-2

Basic information

• Product Name: (R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
• Synonyms: (R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
• CAS NO: 1312692-16-2
• Molecular Weight: 355.44
• Mol File: 1312692-16-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(1312692-16-2)
• EPA Substance Registry System: (R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(1312692-16-2)

Safety Data

• Hazardous Substances Data: 1312692-16-2(Hazardous Substances Data)

Upstream product

• 343781-55-5 2,6-dichloro-4-iodo-3-pyridinecarboxylic acid 
• 1312692-15-1 (R)-methyl 6-(2-(tert-butoxycarbonylamino)-3-ethoxypropylamino)-4-cyano-2-(m-tolylamino)nicotinate 
• 1312692-11-7 (R)-tert-butyl 1-amino-3-ethoxypropan-2-ylcarbamate 
• 1312692-12-8 (R)-tert-butyl 1-azido-3-ethoxypropan-2-ylcarbamate 
• 666718-81-6 (R)-tert-butyl 1-ethoxy-3-hydroxypropan-2-ylcarbamate 
• 1312690-83-7 methyl 6-chloro-4-cyano-2-(m-tolylamino)nicotinate 
• 1309866-40-7 2,6-dichloro-4-iodo-nicotinic acid methyl ester 
• 1312690-81-5 methyl 2,6-dichloro-4-cyanonicotinate 
• 148493-37-2 2,6-dichloro-3-iodo-pyridine 
• 104839-00-1 N-(tert-butoxycarbonyl)-O-ethylserine 

Relevant articles and documents

FUSED HETEROAROMATIC PYRROLIDINONES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.